Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Supports Ketek as Second-Line for CAP; Suggests Black Box

Executive Summary

Sanofi-Aventis' Ketek should not be the first-line treatment for community acquired pneumonia, members of an FDA advisory panel cautioned when they recommended continued marketing of the antibiotic for CAP

You may also be interested in...



Rx Industry Faces Wave of Personal Injury Suits; Avandia To Test Honed Skills

Some of the biggest names in product liability litigation will be flocking to a conference in Chicago July 13 to focus on one drug: Avandia. Mark Lanier, who won the largest jury verdict against Vioxx, is co-chairing the event. Other headliners include Christopher Seeger, a lead plaintiffs attorney in the federal Vioxx litigation, and Karen Barth Menzies, who has spearheaded dozens of cases against antidepressant products

Rx Industry Faces Wave of Personal Injury Suits; Avandia To Test Honed Skills

Some of the biggest names in product liability litigation will be flocking to a conference in Chicago July 13 to focus on one drug: Avandia. Mark Lanier, who won the largest jury verdict against Vioxx, is co-chairing the event. Other headliners include Christopher Seeger, a lead plaintiffs attorney in the federal Vioxx litigation, and Karen Barth Menzies, who has spearheaded dozens of cases against antidepressant products

Ketek Superiority Trials May Hold Key To Sales After Safety Relabeling

Sanofi-Aventis recently conducted superiority trials for its antibiotic Ketek, and the results could determine whether the drug bounces back from an FDA decision to withdraw two indications from the drug's label

Related Content

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel